GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Shiller PE Ratio

Ocugen (FRA:2H51) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocugen Shiller PE Ratio Historical Data

The historical data trend for Ocugen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Shiller PE Ratio Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocugen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocugen's Shiller PE Ratio

For the Biotechnology subindustry, Ocugen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ocugen's Shiller PE Ratio falls into.



Ocugen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ocugen's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ocugen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Ocugen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -40.923 100.560 -53.627
201409 -51.642 100.428 -67.762
201412 82.720 99.070 110.029
201503 -33.263 99.621 -43.999
201506 -31.006 100.684 -40.581
201509 -32.610 100.392 -42.805
201512 -34.700 99.792 -45.821
201603 -32.327 100.470 -42.400
201606 -32.573 101.688 -42.211
201609 -37.421 101.861 -48.411
201612 -35.834 101.863 -46.357
201703 -15.147 102.862 -19.405
201706 -13.350 103.349 -17.022
201709 -11.578 104.136 -14.651
201712 -13.182 104.011 -16.701
201803 -25.303 105.290 -31.668
201806 -6.677 106.317 -8.276
201809 -12.341 106.507 -15.269
201812 -7.603 105.998 -9.452
201903 -6.372 107.251 -7.829
201906 -1.593 108.070 -1.942
201909 -3.223 108.329 -3.921
201912 0.212 108.420 0.258
202003 -0.063 108.902 -0.076
202006 -0.169 108.767 -0.205
202009 -0.059 109.815 -0.071
202012 -0.017 109.897 -0.020
202103 -0.034 111.754 -0.040
202106 -0.108 114.631 -0.124
202109 -0.043 115.734 -0.049
202112 -0.062 117.630 -0.069
202203 -0.082 121.301 -0.089
202206 -0.085 125.017 -0.090
202209 -0.101 125.227 -0.106
202212 -0.094 125.222 -0.099
202303 -0.075 127.348 -0.078
202306 -0.092 128.729 -0.094
202309 -0.056 129.860 -0.057
202312 -0.037 129.419 -0.038
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ocugen  (FRA:2H51) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ocugen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ocugen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (FRA:2H51) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines